Divis Laboratories Ltd

- No specific mention of any current or future fundraising through debt or equity in the document. - The company plans to fund the ₹650-700 crore capacity addition/project entirely through internal accruals. - Discussions indicate continued investments funded from internal resources rather than external fundraising. - No announcements or hints about issuing new equity or taking on debt were made during the call.

- Divi's Laboratories is planning a long-term supply agreement with an MNC supported by a capacity addition with an investment of ₹650 to ₹700 crores, funded from internal accruals. - The proposed ₹650-700 crore facility is expected to be operational by January 2027. - Unit III facility near Kakinada is progressing well with phase-wise production starting in FY 2024-25. - Total capex guidance for FY 25 is around ₹1,500 to ₹1,600 crores, including balance spend of about ₹800 crores from Phase I and another ₹700 crores planned. - Phase II capex will commence after commercializing Phase I. - The ₹700 crore dedicated project has a long gestation (~2.5 years) due to early-stage development and regulatory validations. - The company is investing in specialized technologies (flow chemistry, mechanochemistry, etc.) to improve cost efficiency and green chemistry adherence.

- Divi's aims for consistent double-digit year-on-year growth in sales and revenue going forward. - Volume growth is expected to support growth despite continued generic price erosion. - Investment in new technologies and capacity expansions (₹1,500 crores capex for FY25 and beyond) will enable scaling up and future revenue increase. - Growth engines include generics, custom synthesis (CS), contrast media, new product pipelines, and peptide projects. - Custom synthesis segment and new projects in clinical phases are expected to fuel future growth. - Generic volumes continue to increase steadily, with new generics like Ticagrelor, Lacosamide, and Brivaracetam expected to contribute from FY26-27 onward. - Completion and commercialization of large-scale projects (e.g., ₹650-700 crores capacity addition) anticipated around 2027 will drive top-line growth. - The company expects to maintain or grow market share in both generics and CS segments despite pricing pressures.

- Divi's Laboratories expects continued double-digit sales growth year-on-year, driven by both generic and Custom Synthesis (CS) businesses. - Generic business volume growth remains strong despite ongoing pricing pressure; future generics like Ticagrelor, Lacosamide, and Brivaracetam are expected to contribute from FY26-27 onwards. - CS segment growth is supported by multiple new projects in various clinical phases, with steady value realization from existing projects and expansion in peptide opportunities. - New long-term supply agreements and capacity additions (₹650-700 crores investment) will support growth. - Price erosion in generics is expected to stabilize over 1-2 years, improving margins gradually. - Kakinada facility phase-wise commercialization starting H2 FY25 will add capacity and support revenue/earnings growth. - Margin improvements expected from operational efficiencies and backward integration advantages. - Overall, the outlook for profits/EPS is positive with growth engines maturing and new product launches.

- Divi's Laboratories has experienced a substantial increase in inquiries for Custom Synthesis (CS) projects, including both existing clients and new large MNCs as well as small and mid-tier biotech companies. - The inquiry increase is described as "phenomenal," with projects in various phases (Phase I to Phase III), reflecting strong demand. - The timeline for converted contracts from RFPs to revenue generation can vary, typically ranging from 2-3 years up to 5-7 years depending on the project phase and regulatory approvals. - Divi's is actively engaged with several multinationals with products in Phase III and fast track, indicating a robust order book in the CS segment. - Specific quantification of order book or pending orders is not disclosed due to confidentiality agreements. - The long-term agreements with multinational companies are expected to lead to more opportunities and tie-ups going forward.